Skip to main content

Keeping Up to Date on New Multiple Myeloma Drugs

Hematologic Cancers, Conference Correspondent, ASH Highlights
Conference Correspondent 
Leslie Lauersdorf addresses the challenges associated with staying abreast of the side effects, management, and sequencing for new multiple myeloma treatments.

Related Items

Polatuzumab Vedotin plus R-CHP Outperforms Standard of Care in Treatment of DLBCL
TOP - March 2022 Vol 15, No 2
ASH Highlights, Lymphoma
Time-Limited Venetoclax-Based Regimens Demonstrate Promising Efficacy in Fit Patients with CLL
TOP - March 2022 Vol 15, No 2
ASH Highlights
Mosunetuzumab Induces Deep Remissions in Patients with Relapsed/Refractory Follicular Lymphoma
By William King
TOP - January 2022 Vol 15, No 1 – Online Only
ASH Highlights
Results from 2 Studies Provide Insights on Antibody Response to COVID-19 Vaccines in Patients with Hematologic Malignancies
By William King
TOP - January 2022 Vol 15, No 1 – Online Only
ASH Highlights